Highly innovative blood-plasma purification to boost immunity and self-healing powers
Large quantities of toxins can be removed from the body very effectively by purifying blood plasma, and even more so by preceding this with a treatment involving toxin-binding substances known as chelates. A special “blood-plasma filtration process” known as INUSpherese® has been developed to swiftly and
effectively eliminate toxins on a large scale. As a certified INUS partner in Switzerland, the Alpstein Clinic offers this procedure, and, through its close cooperation with the INUS Center in Cham (Germany), also has access to a wealth of global experience in apheresis therapy
Benefits for INUSpheresis® treatments:
- Elimination of disease-fostering substances and environmental toxins from the blood
- Preservation of fundamental proteins, electrolytes, and antibodies
- Gentle and low risk of side effects
- May be performed as a day procedure, approx. 2 hours
- May be integrated into holistic medicine
The therapeutic INUSpheresis® concept
Apheresis (hemodialysis) as an effective, clinically proven therapy option and disease-prevention treatment.
State-of-the-art smart filter systems guarantee a gentle “effective detox” that is still also tailored to individual patient needs. The procedure’s advantage lies in the fact that it eliminates not only toxins ingested from external sources, but also allergens, metabolic waste, inflammatory messengers, infection toxins, and harmful proteins. Originally called Chemopherese® and now further developed as INUSpherese®, apheresis is an innovative part of the INUS concept. Based on 6000 years of experience gained by phlebotomy therapists from all the world’s
cultures, this modern-day treatment is a special form of high-tech plasma purification and immunomodulation for chronic and acute metabolic and immune disorders (autoimmune diseases).
The original Chemopherese® concept particularly revolved around eliminating toxins, i.e. chemicals such as pesticides and organic solvents, as well as heavy metals. INUSpherese® then enhanced this by also removing pathological proteins and immune complexes, metabolic waste, infection toxins, allergens, and inflammatory messengers.
Chemopheresis® in international medicine
Chemopherese® is not a treatment specific to Swiss or German medicine, but was rather developed by INUS in Bavaria. The system is based on the blood-purification process, which has been tried and tested over the last thirty years. There are currently seventeen national apheresis societies, as well as three international societies: the World Apheresis Association (WAA), the International Society for Apheresis (ISFA), and the European Society for Hemapheresis.
INUSpheresis® at the Alpstein Clinic
As an INUSpherese® Center, the Alpstein Clinic has both a national and international focus. In its international activities, it thus reserves the right to also consult the guidelines and recommendations issued by other international apheresis societies (e.g. the Japanese Society for Apheresis, the American Society for Apheresis, the World Apheresis Association, the International Society for Therapeutic Apheresis, guidelines published by the US Food and Drug Administration etc.) when issuing indications or answering questions relating to apheresis treatment.
How INUSpheresis® works at the Alpstein Clinic
The INUSpheresis® process
The Alpstein Clinic uses INUSpherese® toxin-removal process that is tailored to individual patient needs. There are three different types of filters, whose efficacy has been proven in clinical studies. The process is considered very effective with a high degree of tolerance.
Important: The INUSpherese® process performed at our clinic is NOT a PLASMA EXCHANGE, and thus does not have any of the side effects produced by that procedure. Only pathogenic loads – not electrolytes or other healthy components – are filtered out.
The process used at the Alpstein Clinic involves conducting chemical and biochemical analyses on the filtered-out waste to measure the amount of eliminated toxins and residual plasma. The analysis results are stored and serve to monitor the treatment process, as well as identify disease history and further plan a holistic treatment program.
TAKING AND RESTORING BLOOD
Blood is taken and restored via the arm veins using special cannulas. Treatment takes approx. two hours, and is performed by the Alpstein Clinic’s specially trained and qualified medical staff and assistants.
INDICATIONS AND MONITORING
As an anesthesiology and emergency-medicine specialist trained in therapeutic apheresis, Frank Oberle is responsible for indications and monitoring at our clinic.
Quality assurance for the treatment is governed by INUS’ quality management system (compliant with ISO 9001-2008). The procedure involves you lying in an electrically adjustable treatment bed, though you do not have to disrobe completely. It lasts approx. two hours and takes place in a pleasant, relaxed setting, with technical monitoring and staff attendance guaranteed at all times.
Suitable for sensitive patients with acute, chronic, and unclear diseases
The indications for INUSpherese® must be seen as (last-resort) treatment attempts within the INUS treatment program when no other conventional or alternative medical options are suitable/known and/or these involve severe, unjustifiable side effects from conventional treatment strategies (see pharmacotherapy, chemotherapy).
Through a special derivation method, the INUSpherese® process employed at the Alpstein Clinic enables highly concentrated plasma to be obtained for diagnostic purposes. This plasma can help explain the history and background of the disease, and ultimately ensure this can be used to create a holistic pathogenetic treatment program. The data produced is collected and analyzed
in an anonymized database, and published internationally, thus constituting a very important component of evidence-based medicine.
Greater Prospects for Treatment Options
Special new filters make it possible to catch tumor cells or viruses circulating in the blood, and filter them out. This will provide another treatment option not only for patients with environmental toxicity, but also cancer patients and patients suffering from diseases such as severe hepatitis. At the Alpstein Clinic, we firmly believe this method is yet another step in the right direction for our patients, whose health is our utmost priority. We look forward to providing you with detailed information and explanations on the INUSpherese® procedure, and outlining its effects and positive aspects.
Internationally recognized indications for the INUSpherese® treatment
Alzheimer’s disease – also referred to simply as Alzheimer’s – is the most common form of dementia and an incurable disorder of the brain. Due to the death of nerve cells in the brain, people with Alzheimer’s become increasingly forgetful, confused and disoriented.
Toxicity from heavy metals, solvents, and other environmental toxins
Toxicity from heavy metals, solvents, and other environmental toxins causing clinical symptoms of autoimmune diseases and/or nervous diseases and/or skin diseases (e.g. fibromyalgia, blistering skin diseases, toxic nerve damage, kidney damage, MCS, CFS, ciguatera poisoning)
Lyme disease as severely progressing late-stage Lyme disease
Lyme disease as severely progressing late-stage Lyme disease, which can no longer be controlled conservatively (CFS/Guillain-Barre syndrome resistant to immunoglobulin therapy/severe treatment-resistant autoimmune diseases, such as rheumatism, systemic collage¬noses, lupus diseases, cardiomyopathies based on proven autoantibodies affecting the heart in the case of Lyme disease)
Chronic fatigue syndrome
Chronic hepatitis C
(covered by national medical insurance category 1 in Japan)
(EPH = edema-proteinuria-hypertension), Clinical symptoms during pregnancy, triggered by specific antibodies targeting the placenta’s blood vessels and the mother’s vascular system
Hypertension (high blood pressure)
Positive detection of arterial alpha 1 and/or angiotensin 1 antibodies, impossible or very difficult to treat with conventional pharmacotherapy
Based on studies conducted by the Canadian and American Society for Apheresis
Multiple chemical sensitivity syndrome (MCS)
Hyperbilirubinemia in congenital metabolic disorders of the liver, with risk of brain damage